TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* Active IBS diagnosis by a gastroenterologist~* Generalized Anxiety Disorder diagnosed by DSM-IV TR criteria and the Mini International Neuropsychiatric Interview for the DSM-IV (Mini)~* No changes in any non study medication once starting the study~Exclusion Criteria:~* Current diagnoses of Major Depressive Disorder, Panic Disorder, Social Phobia, Post Traumatic Stress Disorder, Obsessive Compulsive Disorders, Eating Disorders, Somatoform Disorders, Drug or alcohol abuse or dependence, or severe personality disorder~* Lifetime history of any Bipolar Disorder or Psychotic Disorder~* Concurrent GI disorders falling outside of Rome III Functional GI disorders~* Pregnant women or sexually active female subjects not using medically acceptable method of contraception~* Current suicidal ideation~* Unstable medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): Two weeks of placebo run in followed by 12 weeks of Duloxetine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Booster and Catch-up Vaccination With Vaccine GSK1024850A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects for whom the investigator believes that their parent(s)/ guardian(s) can and will comply with the requirements of the protocol.~* Written, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child/ward. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~For primed subjects:~* Completion of the full vaccination course in study NCT00814710.~* 9-18 months of age at the time of randomization.~* Group A: 9-18 months of age at the time of booster vaccination.~* Group B: 15-18 months of age at the time of booster vaccination.~For unprimed subjects (Group C):~* Enrolled in study NCT00814710.~* 12-18 months of age at the time of first vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product within 30 days preceding the vaccination, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.~* Administration of immunoglobulins and/or any blood products within three months preceding the vaccination or planned administration during the study period.~* Administration of any pneumococcal vaccine since the end of study NCT00814710.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrolment.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
- Group B (Type: EXPERIMENTAL): Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
- Group C (Type: EXPERIMENTAL): Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes treated with a lifestyle or metformin (any dose)~* waist circumference \> 88 cm in women and \> 92 cm in men~* BMI 27-40 kg/m2~* triglycerides between 1.0 - 4.0 mmol/L~* LDL \< 4.5 mmol/l~Exclusion Criteria:~* Type 1 diabetes~* Apo E2/2 phenotype~* ALT/AST \> 3x ULN~* GFR \< 60 ml/min, clinically significant TSH outside normal range~* Lipid-lowering drugs other than statins within 6 months~* Current treatment with pioglitazone, insulin, sulphonylureas, gliptins, glinides, SGLT-2 inhibitors or thiazide diuretics (at a dose of \> 25 mg / day)~* Blood pressure \> 160 mmHg systolic and/or \> 105 diastolic~* History of pancreatitis or stomach / other major bleeding, thyroid neoplasia, persistent hypothyroidism or persistent hyperthyroidism~* Any medical condition that puts the patient in the risk of dehydration~* Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.~* Females of childbearing potential who are not using adequate contraceptive methods~* Subjects who have experienced side-effects previously from GLP-1 agonists~* Non-compliance or withdrawal of consent~* Any information or clinical event described in liraglutide SPC that is a contraindication for the use of liraglutide

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): Liraglutide subcutaneous injection once daily with following dose escalation:~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection once daily with following dose escalation:~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I hypertension (140-159/90-99 mmHg)~* Men and women age 18-65~Exclusion Criteria:~* Congestive heart failure or coronary artery disease~* Blood pressure averaging \>159/99 mmHg or resting heart rate \< 55 bpm~* Serum creatinine \> 1.4 mg/dL~* Asthma or chronic obstructive pulmonary diseases~* Left ventricular hypertrophy by echocardiography or ECG~* Pregnancy~* Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin~* Any history of substance abuse (other than tobacco)~* Concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)~* History of symptomatic bradycardia or heart block

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Initial treatment with metoprolol (Type: ACTIVE_COMPARATOR): The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
- Initial treatment with nebivolol (Type: ACTIVE_COMPARATOR): The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* We will study 30 patients with Type 2 Diabetes or impaired fasting glucose (15 men \& 15 women) who are \> 20 years old.~* Only patients who use lifestyle modification to manage their diabetes and are not on any oral hypoglycemic agents or insulin will be included.~* We will enroll subjects who have fasting glucose concentration greater than 100 mg/dl on two consecutive occasions and have a Body Mass Index between 27-36 kg/m\^2.~Exclusion Criteria:~* We will exclude patients whose blood glucose is above 180 mg/dl. This will avoid the need to perform home glucose monitoring and the potential of unblinding the study by the volunteers.~* Patients taking oral hypoglycemic agents or insulin would be excluded.~* Any diseases such as active cardiovascular disease, liver diseases, kidney failure (males with serum creatinine \>= 1.5mg/dl, females \>=1.4 mg/dl), active endocrinopathies, debilitating chronic disease, anemia, symptoms of undiagnosed illness, history of alcoholism (alcohol use \> 4oz/day) or substance abuse, chronic neurological diseases including Alzheimer's disease, stroke, etc, myopathies or any other active disease that may potentially affect the outcome measures.~* Patients on medicines such as beta blockers, corticosteroids, tricyclics, benzodiazepines, opiates, barbiturates, anticoagulants and any other drugs or preparations that may affect mitochondrial function will be excluded.~* People allergic to any of the class of drug such as lidocaine will also be excluded.~* People with pacemakers, certain aneurysm clips and claustrophobia will also be excluded as they cannot undergo magnetic resonance imaging.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Sensitizer Therapy (Type: ACTIVE_COMPARATOR): Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets were used to match the active comparator drugs and dosing regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status 0 or 1~* Clinically stage 2 or 3 with histologically proven lymph node involvement~* Tumor or lymph node greater than 1.5 cm~Exclusion Criteria:~* Pregnancy or lactation~* Prior chemotherapy or radiotherapy for any malignancy~* Documented history of cardiac disease contraindicating anthracyclines~* Currently active infection

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FEC3-D3 (Type: ACTIVE_COMPARATOR): 3 cycles of FEC followed by 3 cycles of Docetaxel~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks
- AC4-D4 (Type: NO_INTERVENTION): 4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ED90 for Hyperbaric Bupivacaine in Super Obese Parturients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiology (ASA) class 2 and 3~* English speaking~* Gestational age \> 36 weeks~* Scheduled for cesarean delivery under combined spinal epidural anesthesia~* 18 years or older~* BMI \> 50 kg/m2~Exclusion Criteria:~* History of past or current intravenous drug or chronic opioid abuse~* Allergy or contraindication to any study medications~* Intrapartum cesarean delivery under epidural anesthesia~* Cesarean delivery under general anesthesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Starting dose of Bupivacaine (9 mg) (Type: EXPERIMENTAL): The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
- Subsequent dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Ulcerative Colitis (UC) at active phase who are defined to show Ulcerative Colitis-Disease Activitiy Index (UC-DAI) score of 3 or higher but 8 or less, and bloody stool score of 1 or higher~Exclusion Criteria:~* Patients with serious or higher according to diagnostic critera of seriousness and patients with chronic persistent type and with acute serious type in the classification by clinical course

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Asacol® (Type: EXPERIMENTAL): Import Mesalazine
- Mesalazine (Type: ACTIVE_COMPARATOR): Marketed Mesalazine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have presbyopia.~Exclusion Criteria:~Subjects must not:~* Have any contraindications to the study medications or diagnoses that would confound the study.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CSF-1 (Type: EXPERIMENTAL): One drop bilaterally twice daily for approximately 2 weeks.
- Vehicle (Type: PLACEBO_COMPARATOR): One drop bilaterally twice daily for approximately 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women on adequate contraception if they are of child-bearing age.~* Meet revised ACR criteria for RA.~* Stable doses of DMARDS,biologic agents and or corticosteroids for at least 3 months.~Exclusion Criteria:~* Pregnant or lactating women.~* Current smokers or individuals who smoked in the last 6 months.~* Diagnosis of Diabetes, heart failure, or infection.~* Current diagnosis of malignant disease except for basal cell or squamous cell carcinoma of the skin.~* No active liver disease.~* No cholesterol-lowering medications or oral hypoglycemic agents.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone then placebo (Type: OTHER): Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
- placebo then study drug (pioglitazone) (Type: OTHER): Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old to menopause~* polycystic ovary syndrome (NICHD criteria)~* BMI of 30 kg/m² or higher~* poor response to previous treatment with metformin for at least 3 months~Exclusion Criteria:~* type 1 or type 2 diabetes mellitus~* history of carcinoma~* Cushing's syndrome or congenital (non-classic) adrenal hyperplasia~* personal or family history of MEN 2~* significant cardiovascular, kidney or hepatic disease~* the use of medications known or suspected to affect reproductive or metabolic functions~* the use of statins, within 90 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: ACTIVE_COMPARATOR): In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
- liraglutide (Type: ACTIVE_COMPARATOR): In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
- metformin and liraglutide (Type: ACTIVE_COMPARATOR): In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The main criteria for inclusion in the study were as follows:~  * A diagnosis of primary antibody deficiency;~ * No lower or upper age limit (any age was eligible);~ * With stable disease and receiving immunoglobulin (IVIG or SCIG) therapy for at least six months prior to starting the study;~ * Written informed consent (patient/parent/guardian).~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subgam® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be at least 18 years of age~* drink heavily at least once per month on average (≥5 drinks) or drink more than 14 drinks per week~* have a confirmed diagnosis of HIV/AIDS~* be a male who has had sex (oral or anal) with a male partner in the past 3 months.~Exclusion Criteria:~* current intravenous drug use~* currently psychotic, suicidal, or manic~* are currently being treated or have been treated in the past 3 months for an HIV-related opportunistic infection~* currently receiving treatment for an alcohol or drug problem

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment as usual (Type: NO_INTERVENTION): Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
- Brief Alcohol Intervention (Type: EXPERIMENTAL): Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete